Welcome to our dedicated page for Zentalis Pharmaceuticals news (Ticker: ZNTL), a resource for investors and traders seeking the latest updates and insights on Zentalis Pharmaceuticals stock.
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) is a clinical-stage biopharmaceutical company focused on oncology, and its news flow centers on the development of azenosertib (ZN‑c3), an investigational WEE1 inhibitor. Company updates highlight progress in Cyclin E1-positive platinum-resistant ovarian cancer (PROC), where azenosertib is the lead program, as well as exploratory work in other tumor types and combination regimens.
Visitors to this ZNTL news page can follow announcements on the DENALI Phase 2 trial, a multi-part, registration-intent study in PROC. Zentalis uses press releases to report milestones such as completion of enrollment in DENALI Part 2a, dose confirmation plans, and expectations for topline data from Part 2, which the company states could support a potential accelerated approval pathway, subject to FDA feedback. News items also describe alignment with the U.S. Food and Drug Administration on the design of ASPENOVA, a planned Phase 3 randomized, confirmatory trial comparing azenosertib to standard-of-care chemotherapy in Cyclin E1-positive PROC.
Beyond ovarian cancer, Zentalis news covers scientific presentations and broader development activity for azenosertib, including Phase 1 data in advanced solid tumors, Cyclin E1 biomarker findings, the TETON Phase 2 trial in uterine serous carcinoma, and a Phase 1 combination study with trastuzumab deruxtecan in HER2-expressing cancers. The company also issues regular financial results and operational progress releases, detailing research and development spending, cash position, and restructuring steps intended to prioritize late-stage development of azenosertib.
Additional ZNTL headlines include corporate governance and personnel changes, such as leadership transitions in the Chief Legal Officer role, board resignations, and equity inducement grants under Nasdaq Listing Rule 5635(c)(4). Investors and observers can use this page to monitor how Zentalis links its clinical milestones, biomarker strategy and financial resources as it advances azenosertib in PROC and other tumor settings.
Zentalis Pharmaceuticals, a clinical-stage biopharmaceutical company focusing on oncology treatments, announced the grant of 204,850 non-qualified stock options to seven new employees on December 1, 2022. This grant was made under the 2022 Employment Inducement Incentive Award Plan, complying with Nasdaq Listing Rule 5635(c)(4). The exercise price of the options is set at $21.09 per share, aligning with the closing price on the grant date. These options have a 10-year term and will vest over four years, contingent on continued employment.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced Q3 2022 financial results, highlighting a robust cash position of $422 million, sufficient to fund operations into 2025. The company is advancing its promising Wee1 inhibitor, ZN-c3, with ongoing studies, including monotherapy and combination therapies. A biomarker-driven trial focusing on Cyclin E driven high-grade serous ovarian cancer has been initiated, while collaborations with Pfizer and GSK aim to enhance clinical development. R&D expenses decreased to $42.2 million, while general and administrative expenses rose to $12 million due to stock-based compensations.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced that its CEO, Kimberly Blackwell, will engage in a fireside chat at the Stifel 2022 Healthcare Conference on November 15, 2022, at 1:15 p.m. ET. This event highlights Zentalis's ongoing commitment to developing small molecule therapeutics targeting cancer pathways. A webcast will be available via the company's website, offering insights into their innovative oncology pipeline, which includes notable candidates like ZN-c3 and ZN-d5.
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) announced on November 1, 2022, the grant of non-qualified stock options for 350,025 shares to four newly hired employees. This grant is part of their 2022 Employment Inducement Incentive Award Plan, complying with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $25.60 per share, equal to the stock's closing price on the grant date, and will vest over four years. Zentalis focuses on developing small molecule cancer therapeutics, with various oncology candidates in their pipeline.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced a collaboration with Pfizer to initiate a Phase 1/2 dose escalation study of ZN-c3, a selective Wee1 inhibitor, in treating BRAF V600E-mutated colorectal cancer. This study aims to assess the combination of ZN-c3 with encorafenib and cetuximab, part of the BEACON regimen. With 21% of metastatic colorectal cancer patients harboring BRAF mutations, this collaboration addresses a significant unmet medical need. Patient enrollment is anticipated to start in Q1 2023, offering hope for improved treatment options in this aggressive cancer type.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) has appointed Dr. Mark Lackner as Chief Translational Officer and Head of Biomarker Strategy. Dr. Lackner, a seasoned expert in oncology and biomarker development, brings over 20 years of experience from IDEAYA Biosciences and Genentech. This strategic hire aims to enhance Zentalis' clinical strategy and biomarker capabilities, particularly for the ongoing ZN-c3 biomarker trial. CEO Dr. Kimberly Blackwell emphasized that strengthening the executive team is crucial for advancing the company’s oncology pipeline, which includes promising candidates such as ZN-c3, ZN-d5, and ZN-c5.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced the granting of equity awards to Dr. Carrie Brownstein, the new Chief Medical Officer, on October 3, 2022. The awards include non-qualified stock options to purchase 300,000 shares, 100,000 performance-based options, and 100,000 restricted stock units. The stock options have an exercise price of $22.21 per share, aligning with the closing price on the grant date. The grants were made under the 2022 Employment Inducement Incentive Award Plan, aiming to attract qualified personnel to Zentalis.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) has announced the promotion of co-founder Kevin Bunker, Ph.D., to Chief Scientific Officer. In this role, he will lead R&D efforts in San Diego, focusing on advancing the preclinical pipeline and refining the Integrated Discovery Engine. Dr. Bunker, previously COO, has contributed significantly to the company's achievements, including developing leading oncology drug candidates like ZN-c3 and ZN-d5. The company's mission is to improve patient outcomes through innovative small molecule therapeutics targeting cancer pathways.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) has appointed Dr. Carrie Brownstein as Chief Medical Officer, effective October 3, 2022. Bringing over 20 years of experience in oncology and hematology, Dr. Brownstein previously served as CMO of Cellectis and held key roles at Celgene, contributing to the approval of several novel products. Zentalis focuses on developing small molecule therapeutics for cancer treatment, with lead programs ZN-c3 and ZN-d5. Dr. Brownstein aims to leverage her expertise to enhance clinical advancement at Zentalis.
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) announced the appointment of Dr. Jan Skvarka to its Board of Directors, bringing over 30 years of experience in the biopharmaceutical industry. Dr. Skvarka has a proven track record of leading clinical-stage companies and has successfully transformed Trillium Therapeutics, resulting in a significant acquisition by Pfizer. His expertise is expected to guide Zentalis as it develops its lead candidates, ZN-c3 and ZN-d5, which target various cancers. Zentalis aims to advance its pipeline of innovative cancer therapeutics amidst ongoing industry challenges.